Phreesia Inc Dossier
|
SectorHealth Care IndustryHealth Care Technology Beta (adjusted)0.90 Intrinsic Value No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference. Market Price $10.36Price as of 1 Oct 2026 Data confidence Sign in to view data confidence Market Cap $643.1M Enterprise Value $570.4M Shares Outstanding 64.5M diluted Moat Rating None Next Earnings Date8 Dec 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Phreesia has successfully crossed the threshold into GAAP profitability and robust free cash flow generation, supported by its dominant position in patient intake and the strategic integration of AccessOne. However, near-term upside is heavily constrained by a lack of visibility in its Network Solutions segment, where pharmaceutical clients have reduced second-half spending commitments. This dynamic forced a major revenue guidance cut in March 2026, triggering a steep stock decline and a wave of securities class action lawsuits. While the stock trades at a historically low valuation of ~1.17x TTM sales, the legal overhang and weakened pharma marketing spend warrant a cautious Hold stance until visibility improves. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$9.00 Mean target$13.94 High · most bullish analyst$20.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Pharma client commitments deteriorate further, causing Phreesia to miss the low end of its $510 million fiscal 2027 revenue guidance. The ongoing securities class action lawsuits lead to substantial settlement costs or prolonged legal expenses. Restructuring savings fail to materialize, and client churn increases as competitors like Luma Health and Weave Communications capture market share in the independent provider segment. Base CaseCentral scenario Phreesia successfully integrates AccessOne, driving payment solutions growth and maintaining mid-single-digit client expansion. The company achieves its revised fiscal 2027 revenue guidance of $510 million to $520 million and meets its Adjusted EBITDA target of $125 million to $135 million. Operating leverage from the May 2026 restructuring and AI-driven automation offsets the soft pharmaceutical marketing spend in the second half of the year. Bull CaseUpside scenario Phreesia represents a high-quality SaaS and fintech speculation at rock-bottom prices following market capitulation over guidance. The bull case is underpinned by a clear shift to sustained profitability, robust double-digit revenue growth driven by client expansion, and strong institutional backing with institutions owning over 92% of the stock and buying on balance. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |